Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

By sjmartinez • September 27, 2022

Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022 Aug 19:S1558-7673(22)00174-4. doi: 10.1016/j.clgc.2022.08.006. Epub ahead of print. PMID: 36155169.

Tags: Bladder cancer, Checkpoint Inhibitor, Hematology/Oncology, immunotherapy, Outcomes, Platinum resistance, Publications

Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper-Progression of Disease

Fine SA, Lim SY, Siena NM, de Jesus AB, Goh T, Markus L, Russell TA, Kendal JK, Lofftus SY, Shehata MS, Dao HB, Lee A,[...]

Elevated Adrenocorticotropic Hormone After Adrenalectomy or Adrenal Ablation and Immune Checkpoint Inhibitors: Adrenal Insufficiency Is Not Always the Culprit

Shabsovich D, Kathuria-Prakash N, Zhang J, Cabral M, Lopez L, Sumal A, Drakaki A. Elevated Adrenocorticotropic Hormone After Adrenalectomy or Adrenal Ablation and Immune Checkpoint[...]

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)

Wong MK, Milhem MM, Sacco JJ, Michels J, In GK, Couselo EM, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Wise-Draper TM, Bowles TL, Tsai[...]